Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by research analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock. Chardan Capital’s price objective indicates a potential upside of 109.58% from the stock’s current price.

Separately, D. Boral Capital reissued a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Tuesday.

Coya Therapeutics Trading Up 3.2 %

NASDAQ:COYA opened at $6.68 on Thursday. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.24. The stock has a market cap of $111.60 million, a P/E ratio of -10.28 and a beta of 0.31. The stock has a 50 day simple moving average of $6.33 and a 200 day simple moving average of $6.49.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.14. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, sell-side analysts forecast that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

Several large investors have recently bought and sold shares of COYA. Geode Capital Management LLC raised its stake in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after acquiring an additional 4,485 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Coya Therapeutics during the 4th quarter valued at $401,000. CM Management LLC grew its position in Coya Therapeutics by 11.1% during the 4th quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $917,000 after acquiring an additional 15,941 shares during the last quarter. AIGH Capital Management LLC increased its holdings in Coya Therapeutics by 85.0% in the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock worth $6,883,000 after purchasing an additional 551,725 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Coya Therapeutics in the 4th quarter valued at approximately $59,000. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.